Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement...

A Emergent BioSolutions anuncia a concessão de autorização de introdução no mercado em cinco países da UE da sua vacina por via oral contra a febre tifoide; expande a disponibilidade na Europa GAITHERSBURG, Maryland, May 20, 2019 (GLOBE NEWSWIRE) -- A Emergent BioSolutions Inc. (NYSE: EBS) anunciou hoje que foi bem-sucedida na obtenção da autorização de introdução no mercado da sua vacina...

Emergent BioSolutions gibt Genehmigung der Marktzulassung in fünf EU-Ländern für seinen oralen Typhus-Impfstoff bekannt; Ausweitung der Verfügbarkeit in Europa GAITHERSBURG, Maryland, May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) gab heute bekannt, dass es erfolgreich die Marktzulassung für seinen oralen Typhus-Impfstoff...

Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine...